Evidence-based dosing protocols organized by condition and species. Built by pharmaceutical scientists for informed veterinary professionals and researchers.
The primary tissue repair peptide. Promotes angiogenesis, accelerates tendon/ligament healing, and protects GI mucosa. Most versatile peptide in veterinary practice.
| Species | Dose | Route | Cycle |
|---|---|---|---|
| Dog | 2–5 mcg/kg once daily | SC injection | 4–8 weeks |
| Cat | 100–200 mcg once daily | SC injection | 4–6 weeks |
| Horse | 0.5–2 mcg/kg once daily | SC or IA | 6–8 weeks |
Indications: Tendon tears, ligament injuries, GI ulcers/IBD, wound healing, post-surgical recovery, joint inflammation
⚠ Contraindicated in active malignancy
The gold standard in equine recovery. Promotes systemic muscle fiber repair, reduces inflammation, and accelerates tendon remodeling. Trusted by elite equine programs.
| Species | Loading (Wk 1–4) | Maintenance |
|---|---|---|
| Dog | 2.5 mg SC 2×/wk | 2.5 mg SC weekly |
| Horse | 10–20 mg SC 2×/wk | 10 mg SC weekly |
Indications: Muscle tears, tendon injuries, soft-tissue damage, performance maintenance
⚠ Avoid in pregnancy
Copper tripeptide naturally found in plasma. Stimulates collagen I & III synthesis, accelerates wound closure, improves coat quality. Available topical or injectable.
| Route | Dog | Cat | Horse |
|---|---|---|---|
| Topical | 0.1–0.5% cream 1–2×/day | 0.05–0.1% 1×/day | 0.1–0.3% gel 1–2×/day |
| SC injection | 0.5–1 mg 3×/wk | Not preferred | 5–10 mg 3×/wk |
Indications: Wound healing, post-surgical sites, coat/skin health, connective tissue support
Modified GH fragment with dual action: lipolytic AND cartilage-protective. Ideal for overweight dogs with concurrent arthritis. No blood sugar effects.
| Species | Dose | Timing | Cycle |
|---|---|---|---|
| Dog | 300–500 mcg SC daily | Before exercise | 12–16 weeks |
Indications: Obesity with arthritis, cartilage repair, fat metabolism support
The immune system master regulator. Activates NK cells, dendritic cells, and T-cell maturation. Used clinically for 30+ years in human medicine for hepatitis and HIV immune support.
| Species / Condition | Dose | Frequency | Duration |
|---|---|---|---|
| Dog — chronic infection | 900 mcg/m² SC | 2×/week | 4–6 weeks |
| Dog — cancer adjunct | 900 mcg/m² SC | 2–3×/week | Ongoing |
| Cat — FeLV/FIV active | 500 mcg SC | 2×/week | 6–8 weeks |
| Cat — FeLV/FIV maintenance | 500 mcg SC | Weekly | Ongoing |
| Horse | 2–4 mg SC | 2×/week | 4 weeks |
⚠ Use with caution in autoimmune disease; avoid in transplant patients on immunosuppression
C-terminal tripeptide of alpha-MSH. Inhibits NF-κB, reduces IL-6 and TNF-α. Particularly effective for GI inflammation and skin conditions. Synergistic with BPC-157 for IBD.
| Species | Systemic Dose | Route | Topical |
|---|---|---|---|
| Dog | 0.5–1 mg daily | SC | 0.1% cream 2×/day |
| Cat | 0.25–0.5 mg daily | SC | 0.05% cream 1×/day |
| Horse | 1–2 mg daily | SC | 0.1% gel to wound |
GI Protocol: Combine with BPC-157 for synergistic IBD/colitis treatment
The body's primary antioxidant and detoxification molecule. IV/SC delivery bypasses poor oral bioavailability. Critical for liver disease, toxin exposure, and post-anesthesia recovery.
| Species | IV Dose | SC Dose | Frequency |
|---|---|---|---|
| Dog | 200–400 mg slow push | 100–200 mg diluted | 2–3×/week |
| Cat | 100–200 mg diluted | 50–100 mg | 2×/week |
| Horse | 1–2 g slow infusion | 500 mg–1 g | 1–2×/week |
Indications: Hepatic disease, heavy metal toxicity, post-anesthesia, chronic oxidative conditions
CJC-1295 provides sustained GH release over 7–10 days while Ipamorelin adds selective clean GH pulses without cortisol elevation. Synergistic when combined.
| Species | CJC-1295 | Ipamorelin | Timing |
|---|---|---|---|
| Dog | 100 mcg SC | 200 mcg SC | Nightly |
| Horse | 1 mg SC | 500 mcg SC | Nightly |
Indications: Age-related muscle loss, performance maintenance, post-injury GH support
Long-acting IGF-1 analog. Activates muscle satellite cells, promotes protein synthesis. 3× longer half-life than native IGF-1.
| Species | Dose | Cycle | Note |
|---|---|---|---|
| Dog | 20–50 mcg SC daily | 4 wks on, 2 off | Feed before dosing |
| Horse | 100–200 mcg SC daily | 4 wks on, 2 off | Monitor glucose |
⚠ Risk of hypoglycemia — always feed before dosing; avoid in malignancy
GHRH analog. Stimulates physiologic pituitary GH release — maintains natural pulsatile pattern. Safer than exogenous GH.
| Species | Dose | Timing |
|---|---|---|
| Dog | 0.2–0.3 mcg/kg SC | Bedtime daily |
| Horse | 200–400 mcg SC | Nightly |
Synthetic heptapeptide analog of tuftsin. GABAergic + serotonergic anxiolytic. Non-sedating, non-habit-forming. Suitable for long-term daily use.
| Species | Dose | Route | Frequency |
|---|---|---|---|
| Dog | 100–200 mcg/kg | SC or nasal | 1–2×/day |
| Cat | 50–100 mcg/kg | SC or nasal | Once daily |
Indications: Separation anxiety, storm phobia, travel stress, CDS, fear-based behaviors
ACTH synthetic analog. Stimulates BDNF production, reduces neuroinflammation, protects neurons from oxidative damage. Used for cognitive dysfunction and neurological recovery.
| Species | Dose | Route |
|---|---|---|
| Dog | 0.1–0.2 mg/kg daily | SC or nasal |
| Cat | 0.05–0.1 mg/kg daily | SC or nasal |
Delta Sleep-Inducing Peptide. Promotes slow-wave sleep, modulates cortisol/HPA axis. Analgesic and antiepileptic properties. Administer in evening.
| Species | Dose | Timing |
|---|---|---|
| Dog | 25–50 mcg/kg SC | Evening |
| Cat | 10–25 mcg/kg SC | Evening |
Essential coenzyme for mitochondrial energy production, DNA repair, and sirtuin activation. IV/SC delivery achieves far higher bioavailability than oral forms.
| Species | IV Dose | SC Alternative |
|---|---|---|
| Dog | 500 mg over 2–4 hrs | 50–100 mg 2–3×/wk |
| Cat | Not typically IV | 25–50 mg SC 2–3×/wk |
| Horse | 1–2 g slow infusion | 500 mg SC weekly |
Mitochondria-derived peptide. Activates AMPK, improves insulin sensitivity, reduces adipocyte size. Particularly valuable for equine metabolic syndrome (EMS) and insulin-resistant dogs.
| Species | Dose | Frequency |
|---|---|---|
| Dog | 500 mcg – 1 mg SC | 3×/week |
| Horse | 2–5 mg SC | 3×/week |
Pineal tetrapeptide. Stimulates telomerase activity, protects telomeres, normalizes melatonin production. Used in annual anti-aging cycles.
| Species | Total Dose | Protocol |
|---|---|---|
| Dog | 5–10 mg total | 10-day course, 2×/year |
| Cat | 2–5 mg total | 10-day course, 2×/year |
| Horse | 20–30 mg total | 10-day course, 2×/year |
For major injuries, post-surgical recovery, or performance athletes returning from injury. Addresses tissue repair, systemic recovery, collagen synthesis, and inflammation simultaneously.
| Peptide | Dog Dose | Horse Dose | Role | Duration |
|---|---|---|---|---|
| BPC-157 | 3–5 mcg/kg SC daily | 2 mcg/kg SC daily | Primary tissue repair | 6–8 weeks |
| TB-500 | 2.5 mg SC 2×/wk | 15 mg SC 2×/wk | Systemic recovery | 8–12 weeks |
| GHK-Cu | 0.5 mg SC 3×/wk | 5 mg topical/SC | Collagen synthesis | 6–8 weeks |
| KPV | 0.5–1 mg SC daily | 1–2 mg SC daily | Anti-inflammatory | 4–6 weeks |
Comprehensive immune support protocol for FeLV/FIV-positive cats. Addresses immune activation, inflammation, and antioxidant protection.
| Peptide | Dose | Frequency | Role |
|---|---|---|---|
| Thymosin Alpha-1 | 500 mcg SC | 2×/week × 8 wks, then weekly | T-cell activation |
| KPV | 0.25 mg SC | Daily × 4–6 weeks | Anti-inflammatory |
| Glutathione | 100–150 mg SC | 2×/week | Antioxidant + liver support |
Comprehensive anti-aging protocol for senior dogs (7+ years). Addresses muscle preservation, cognitive support, immune maintenance, and cellular energy.
| Peptide | Dose | Frequency | Role |
|---|---|---|---|
| Sermorelin | 0.2 mcg/kg SC | Nightly | GH maintenance |
| Thymosin Alpha-1 | 500 mcg SC | Weekly | Immune maintenance |
| NAD+ | 50–100 mg SC | 2–3×/week | Mitochondrial energy |
| Epithalon | 5–10 mg total | 10-day course, 2×/year | Telomere protection |
| Selank | 100–150 mcg/kg SC | Daily as needed | Cognitive + anxiety |
| Vial Size | BAC Water Added | Concentration | Best For |
|---|---|---|---|
| 5 mg | 1 mL | 5,000 mcg/mL | Large dogs / horses (small volume per injection) |
| 5 mg | 2 mL | 2,500 mcg/mL | Medium dogs (most common) |
| 5 mg | 5 mL | 1,000 mcg/mL | Small dogs and cats (easier to measure small doses) |
| 10 mg | 2 mL | 5,000 mcg/mL | Horses |
| 10 mg | 5 mL | 2,000 mcg/mL | Large dogs, loading protocols |
Use a U-100 insulin syringe. Formula: Volume (mL) = Dose (mcg) ÷ Concentration (mcg/mL)
| Desired Dose | If Concentration = 2,500 mcg/mL | If Concentration = 1,000 mcg/mL |
|---|---|---|
| 100 mcg | 0.04 mL (4 units on U-100) | 0.10 mL (10 units) |
| 200 mcg | 0.08 mL (8 units) | 0.20 mL (20 units) |
| 250 mcg | 0.10 mL (10 units) | 0.25 mL (25 units) |
| 500 mcg | 0.20 mL (20 units) | 0.50 mL (50 units) |
| 1,000 mcg (1 mg) | 0.40 mL (40 units) | 1.00 mL (100 units) |
BPC-157, TB-500, CJC-1295, Ipamorelin, and most other peptides on this site are NOT on the FDA's current GFI #256 authorized bulk substance list for animal drug compounding. Compounding these peptides is legally permissible ONLY under strictly defined conditions. Failure to comply may result in FDA enforcement action.
Permits extralabel use of approved drugs under a valid VCPR. Does NOT automatically authorize bulk compounding.
| Requirement | What It Means |
|---|---|
| Valid VCPR | Veterinarian must have examined the animal and established a diagnosis |
| No adequate approved alternative | Must document why no FDA-approved drug addresses the clinical need |
| Medical necessity documented | Patient record must include diagnosis, rationale for compounded peptide |
| Patient-specific Rx | Every order tied to a specific named animal — no office stock dispensing |
| No food-producing animals | Never use peptides in cattle, swine, poultry, or horses intended for slaughter |
The primary federal guidance governing bulk compounding for animal patients.
| Requirement | Standard |
|---|---|
| API supplier | FDA-registered facility with current COA: identity, purity (>98%), sterility, endotoxin |
| Sterile compounding | Full USP <797> compliance: ISO-5 cleanroom, personnel qualification, environmental monitoring |
| Batch records | Complete documentation: API lot, COA, BUD assignment, sterility testing |
| Labeling | Compound name, concentration, directions, prescriber, patient, pharmacy, "Not for human use" |
| GFI #256 monitoring | Check FDA's current list regularly — enforcement discretion can change |
The following table summarizes the evidence level for each peptide by veterinary species.
| Peptide | Dog Evidence | Cat Evidence | Horse Evidence | Best Study PMID |
|---|---|---|---|---|
| BPC-157 | B — PK + GI fistula | C — Rodent only | A — RCT | 36588717 / Barić 2020 |
| TB-500 | B — Wound healing | C — Rodent only | A — Blinded RCT | 22571474 |
| GHK-Cu | B — Wound healing | C — Extrapolated | C — Anecdotal | Swaim 1993 |
| Thymosin Alpha-1 | B — Class support | B — FeLV/FIV mechanism | C — Extrapolated | 21539607 |
| Ipamorelin / CJC-1295 | A — PK/PD in beagles | No data | B — Class (MK-677) | 9528977 / 16352684 |
| NAD+ | A — RCT senior dogs | C — Extrapolated | C — Extrapolated | PMC11137034 |
| Glutathione | B — Illness correlation | A — Hepatotox RCT | C — Extrapolated | 26623313 / 19143933 |
| SS-31/Elamipretide | A — Canine HF RCT | No data | No data | 26839394 |
| Oxytocin | B — Behavioral RCTs | C — Extrapolated | C — Reproductive | PMC4594226 |
| Gonadorelin | B — Deslorelin review | No data | A — Ovulation RCT | 32923467 / PMC5155133 |
| Selank / Semax | No vet data | No vet data | No vet data | Rodent only |
| MOTS-c | C — Rodent only | No data | C — Theoretical (EMS) | 25730877 |
Evidence levels: A = Randomized controlled trial or strong PK/PD study in target species | B = Controlled study, class-level evidence, or direct mechanistic study in target species | C = Rodent/in vitro data only or class extrapolation | No data = No peer-reviewed veterinary studies found